IXHL Stock Overview
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Incannex Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$12.68 |
| 52 Week Low | US$1.96 |
| Beta | 2.27 |
| 1 Month Change | -30.63% |
| 3 Month Change | -40.64% |
| 1 Year Change | -74.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.27% |
Recent News & Updates
Why Incannex Healthcare's (NASDAQ:IXHL) Earnings Are Weaker Than They Seem
Feb 21
Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth?
Feb 05Shareholder Returns
| IXHL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.7% | -0.6% | 1.0% |
| 1Y | -74.3% | 10.6% | 21.9% |
Return vs Industry: IXHL underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: IXHL underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| IXHL volatility | |
|---|---|
| IXHL Average Weekly Movement | 26.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IXHL's share price has been volatile over the past 3 months.
Volatility Over Time: IXHL's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Joel Latham | www.incannex.com |
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.
Incannex Healthcare Inc. Fundamentals Summary
| IXHL fundamental statistics | |
|---|---|
| Market cap | US$35.24m |
| Earnings (TTM) | US$21.48m |
| Revenue (TTM) | US$691.12k |
1.6x
P/E Ratio51.0x
P/S RatioIs IXHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXHL income statement (TTM) | |
|---|---|
| Revenue | US$691.12k |
| Cost of Revenue | US$0 |
| Gross Profit | US$691.12k |
| Other Expenses | -US$20.79m |
| Earnings | US$21.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | 3,107.79% |
| Debt/Equity Ratio | 0% |
How did IXHL perform over the long term?
See historical performance and comparison